Clinical Trial Update: Safety, Tolerability, Pharmacokinetics and Antitumor Activity of FCN-437c [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial update on FCN-437c assessing safety, tolerability, pharmacokinetics and antitumor activity in breast neoplasms.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Neoplasms

Drugs mentioned

• FCN-437c

Snippet

Sponsor: Ahon Pharmaceutical Co., Ltd. | Conditions: Breast Neoplasms | Phase 1, Phase 2 | Status: UNKNOWN